Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorElephas

About this trial

This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a normal course of their medical management or diagnostic work-up for suspected or confirmed cancer.

Eligibility criteria

Qualifiers

Able and willing to provide informed consent for participation

Age ≥18 years at time of consent.

Have a suspected or confirmed cancer diagnosis that is to be evaluated by means of a biopsy.

Subjects who are newly diagnosed or have suspected cancer must be treatment-naïve at the time of biopsy. All other subjects should have the biopsy performed before starting their next line of treatment.

Disqualifiers

Have a known auto-immune disease or prior condition (prior organ transplant, chronic kidney or liver disease) that renders them ineligible for immunotherapy (IO) treatment.

Severely immunocompromised person(s). Examples include patients on immunosuppressants, HIV positive patients on antiretrovirals, post transplantation patients.

Pregnant person(s).

Trial design

Treatments tested in this trial

  • Biopsy

Treatment groups

2,000 Participants
are divided into 1 treatment group

Sponsors and collaborators